Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients

Antonio Russo, Maria Rosaria Valerio, Maria Antonietta Satolli, Sara Galluzzo, Raffaele Addeo, Gaetano Lanzetta, Mauro Antimi, Michele Caraglia, Bruno Vincenzi, Vincenzo Adamo, Alfredo Berruti, Valentina Leoni, Giuseppe Tonini, Vittorio Fusco, Daniele Santini, Stefania Redana, Giuseppa Ferraro, Ilaria Roato, Filippo Montemurro, Monica Marra & 1 others Prete Del Salvatore

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright © 2011 Spandidos Publications Ltd. All rights reserved.
Lingua originaleEnglish
pagine (da-a)1545-1548
Numero di pagine4
RivistaOncology Reports
Volume25
Stato di pubblicazionePublished - 2011

Fingerprint

Habits
Smoking
Breast Neoplasms
Tobacco Products
Survival
Therapeutics
Nitrosamines
Tobacco
Medical Records
Trastuzumab
DNA
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. / Russo, Antonio; Valerio, Maria Rosaria; Satolli, Maria Antonietta; Galluzzo, Sara; Addeo, Raffaele; Lanzetta, Gaetano; Antimi, Mauro; Caraglia, Michele; Vincenzi, Bruno; Adamo, Vincenzo; Berruti, Alfredo; Leoni, Valentina; Tonini, Giuseppe; Fusco, Vittorio; Santini, Daniele; Redana, Stefania; Ferraro, Giuseppa; Roato, Ilaria; Montemurro, Filippo; Marra, Monica; Del Salvatore, Prete.

In: Oncology Reports, Vol. 25, 2011, pag. 1545-1548.

Risultato della ricerca: Article

Russo, A, Valerio, MR, Satolli, MA, Galluzzo, S, Addeo, R, Lanzetta, G, Antimi, M, Caraglia, M, Vincenzi, B, Adamo, V, Berruti, A, Leoni, V, Tonini, G, Fusco, V, Santini, D, Redana, S, Ferraro, G, Roato, I, Montemurro, F, Marra, M & Del Salvatore, P 2011, 'Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients', Oncology Reports, vol. 25, pagg. 1545-1548.
Russo, Antonio ; Valerio, Maria Rosaria ; Satolli, Maria Antonietta ; Galluzzo, Sara ; Addeo, Raffaele ; Lanzetta, Gaetano ; Antimi, Mauro ; Caraglia, Michele ; Vincenzi, Bruno ; Adamo, Vincenzo ; Berruti, Alfredo ; Leoni, Valentina ; Tonini, Giuseppe ; Fusco, Vittorio ; Santini, Daniele ; Redana, Stefania ; Ferraro, Giuseppa ; Roato, Ilaria ; Montemurro, Filippo ; Marra, Monica ; Del Salvatore, Prete. / Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. In: Oncology Reports. 2011 ; Vol. 25. pagg. 1545-1548.
@article{13e43a44b8334a2c9da35be200276192,
title = "Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients",
abstract = "Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright {\circledC} 2011 Spandidos Publications Ltd. All rights reserved.",
author = "Antonio Russo and Valerio, {Maria Rosaria} and Satolli, {Maria Antonietta} and Sara Galluzzo and Raffaele Addeo and Gaetano Lanzetta and Mauro Antimi and Michele Caraglia and Bruno Vincenzi and Vincenzo Adamo and Alfredo Berruti and Valentina Leoni and Giuseppe Tonini and Vittorio Fusco and Daniele Santini and Stefania Redana and Giuseppa Ferraro and Ilaria Roato and Filippo Montemurro and Monica Marra and {Del Salvatore}, Prete",
year = "2011",
language = "English",
volume = "25",
pages = "1545--1548",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",

}

TY - JOUR

T1 - Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients

AU - Russo, Antonio

AU - Valerio, Maria Rosaria

AU - Satolli, Maria Antonietta

AU - Galluzzo, Sara

AU - Addeo, Raffaele

AU - Lanzetta, Gaetano

AU - Antimi, Mauro

AU - Caraglia, Michele

AU - Vincenzi, Bruno

AU - Adamo, Vincenzo

AU - Berruti, Alfredo

AU - Leoni, Valentina

AU - Tonini, Giuseppe

AU - Fusco, Vittorio

AU - Santini, Daniele

AU - Redana, Stefania

AU - Ferraro, Giuseppa

AU - Roato, Ilaria

AU - Montemurro, Filippo

AU - Marra, Monica

AU - Del Salvatore, Prete

PY - 2011

Y1 - 2011

N2 - Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright © 2011 Spandidos Publications Ltd. All rights reserved.

AB - Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N- nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and ≤10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients. Copyright © 2011 Spandidos Publications Ltd. All rights reserved.

UR - http://hdl.handle.net/10447/109870

UR - http://www.spandidos-publications.com/serveFile/or_25_6_1545_PDF.pdf?type=article&article_id=or_25_6_1545&item=PDF

M3 - Article

VL - 25

SP - 1545

EP - 1548

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

ER -